TCF4 is a DNA-binding transcription factor that is targeted by RUNX1 and MLL-AF9 and that is considered an independent prognostic factor in AML, while CDK6 is involved in the cell cycle. This evidence concerns the gene TCF4 and acute myeloid leukemia.